Ebsworth David R's Form 4 filing
Verona Pharma plc (VRNA) · filed Nov 8, 2023
- Accession no.
- 0001104659-23-115738
- Filed
- Nov 8, 2023
- Trade date
- Nov 6, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market purchases total $316.8K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Ebsworth David RCIK 0001207107 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 6, 2023 | Ordinary Shares | PPurchaseAcquired | +160,000 | $1.98F2 | +$316,800 | 844,643 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported is a weighted average price, and is based on the sale price of the ADSs divided by eight (8). The securities were purchased in multiple transactions at per share prices ranging from $1.9131 to $2.00, equivalent to $15.3050 to $16.00 per ADS. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.